EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Aberrant Methylation Inactivates Transforming Growth Factor β Receptor I in Head and Neck Squamous Cell Carcinoma

Teresita Muñoz-Antonia, Mariclara Torrellas-Ruiz, Jonathan Clavell, Linda A Mathews, Carlos A Muro-Cacho, Adriana Báez

International Journal of Otolaryngology · 2009

DOI: 10.1155/2009/848695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Otolaryngology, 2009. Verfasst von Teresita Muñoz-Antonia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NIMHD NIH HHS, NCRR NIH HHS, NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alterations in TGF- β signaling are common in head and neck cancer (HNSCC). Mutations in TGF- β type II receptor ( T β R-II ) occur frequently in HNSCC while TGF- β type I receptor ( T β R-I ) mutations are rare, suggesting that other molecular alterations in the TGF- β pathway are likely. To identify abnormalities in T β R-I expression we analyzed 50 HNSCCs and correlated the results with clinical-pathologic features.

Methods

Hypermethylation of T β R-I was evaluated via methylation-specific PCR (MSP) and restriction enzyme-mediated PCR (MSRE). Mutations in exons 1 and 7, mRNA and protein expression were analyzed by direct sequencing, semiquantitative RT—PCR and immunohistochemistry, respectively.

Results

T β R-I expression was lost in 83% HNSCCs and was linked to DNA hypermethylation of the CpG-rich promoter region in 62% of the tumors. The variants 9A/6A and Int7G24A were found in two patients.

Conclusions

This study shows that suppression of T β R-I expression in HNSCC is associated with DNA hypermethylation.

Autor:innen und Institutionen

  • Department of Interdisciplinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

Förderung

  • NIMHD NIH HHS
  • NCRR NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Muñoz-Antonia, T., Torrellas-Ruiz, M., Clavell, J., Mathews, L. A., Muro-Cacho, C. A., & Báez, A. (2009). Aberrant Methylation Inactivates Transforming Growth Factor β Receptor I in Head and Neck Squamous Cell Carcinoma. International Journal of Otolaryngology. https://doi.org/10.1155/2009/848695

Vancouver

Muñoz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, Muro-Cacho CA, Báez A. Aberrant Methylation Inactivates Transforming Growth Factor β Receptor I in Head and Neck Squamous Cell Carcinoma. International Journal of Otolaryngology. 2009. doi:10.1155/2009/848695

BibTeX
@article{MuozAntonia2009,
  author = {Muñoz-Antonia, Teresita and Torrellas-Ruiz, Mariclara and Clavell, Jonathan and Mathews, Linda A and Muro-Cacho, Carlos A and Báez, Adriana},
  title = {Aberrant Methylation Inactivates Transforming Growth Factor β Receptor I in Head and Neck Squamous Cell Carcinoma},
  journal = {International Journal of Otolaryngology},
  year = {2009},
  doi = {10.1155/2009/848695}
}
Kostenlos starten →